Are most Lundbeck reps making $120K?

Discussion in 'Lundbeck' started by Anonymous, May 1, 2015 at 7:07 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Good luck pal. Go ahead and jump in the water.... You'll be just like the other posters on here that complain about Lundbeck under paying them. I tried telling you but keep those blinders on. Haha
     

  2. Anonymous

    Anonymous Guest

    Yes. Otsuka pays GREAT and so does Sunovion. Plus, they'll negotiate, and they'll always pay you more than what you were making. Lundbeck...not so much.
     
  3. Anonymous

    Anonymous Guest

    Yep. I agree. Lundbeck pays a bit more than 110 but not much. I could only get 110.
     
  4. Anonymous

    Anonymous Guest

    Yeppers you are correct.
     
  5. Anonymous

    Anonymous Guest

    112 here. Tried for more.
     
  6. Anonymous

    Anonymous Guest

    Hopefully you did not accept unless you were unemployed or making less money!
     
  7. Anonymous

    Anonymous Guest

    Take the base. Wear short skirts. Make doctors/managers "happy". Get good bonus.
     
  8. Anonymous

    Anonymous Guest

    If these salary numbers are true, then a helluva lot of reps, including me, are way underpaid! Not a good thing at all. Nope, not good.
     
  9. Anonymous

    Anonymous Guest

    If you don't make 110 you are extremely underpaid. Sorry fella, that's your own fault though.
     
  10. Anonymous

    Anonymous Guest

    Why would anybody ever accept a low ball over to come work here unless of course they were out of work?
     
  11. Anonymous

    Anonymous Guest

    Because most reps who come here come from primary care and are chasing the specialty sales dream. They do a deal with the devel not knowing and them get buyers remorse 6 months in.
     
  12. anonymous

    anonymous Guest

    I've wondered that too.

    Lundbeck is big pharma now so it's not different.
     
  13. anonymous

    anonymous Guest

    88k - 97k
     
  14. anonymous

    anonymous Guest

    ASM here, interviewing candidates for Gamma. No one is coming on board at 120k, or even 110k for that matter. 105k will be really pushing it and that requires special approval 2 levels above me. Same as when we hired for Beta. Please stop stirring the pot with the lies already. You're creating a salary misconception of this position.
     
  15. anonymous

    anonymous Guest

    Haha you and the insulting low ball offers sux. Drone
     
  16. anonymous

    anonymous Guest

    At least the candidates know some realistic expectations. But can you agree that this salary range is severely underpaid compared to the industry standard for experienced specialty CNS?
     
  17. anonymous

    anonymous Guest

    A good 20k less which shows this companies lack of commitment for building a legit sales force. Underpaying is a quick fix to get a temporary sales force in place. It will blow up within the first 12 months! What a joke!
     
  18. anonymous

    anonymous Guest

    As was said in the "Offer" thread.....

    "I think what many of you are missing is that Lundbeck is a company with many products – not just one new product Rexulti. The company is currently struggling to meet growth goals, with two recently launched products sucking wind and WAY behind forecasts.

    Here is a quote from a FiercePharma article yesterday:
    “But Brintellix's full year 2014 sales rang in at $28.4 million, much lower than the $271 million predicted by EvaluatePharma. And its first-quarter 2015 sales only amounted to $14.8 million.”

    Regarding Northera, the Lundbeck company quarterly report indicated only $6 million in sales in 1Q2015. Q2 is likely to be improved, but nowhere near what the original forecast estimated.

    On top of these, Xenazine – the company’s largest revenue producing product – is losing exclusivity this Saturday (Aug 15 - per FDA Orange Book online). There may or may not be generics launch at that time, but the risk is definitely there.

    And last, and certainly not least, Lundbeck had a new CEO start on May 20 - Kåre Schultz formerly of Novo. It is likely that he will place his stamp on the company strategy (Global as well as US) soon, possibly at the upcoming Q2 earnings release on August 19th. So you may want to follow Lundbeck on any number of financial sites next week.

    So all things considered, there is NO WAY that Lundbeck is in any position to offer high salaries for these new positions. I strongly urge anyone looking for a new job at ANY company to evaluate the company as well as the position. Everything listed in this post is public information and easy to find and piece together – all you have to do is put in a little internet effort."
     
  19. anonymous

    anonymous Guest

    People are starting to leave on a regular basis. Yes, salaries for experienced reps are way under industry standards. I think people are starting to realize here that the famous Lundbeck culture has done a 180 towards big pharma. I have never seen such discontent at Lundbeck before. Everyone is dreading to go to the Rexulti launch meeting. The atmosphere has become one of dread, because of no pipeline, Takeda/Otsuka idiots, low salary, and low bonuses.

    It has been a very fast decline. Very fast indeed.
     
  20. anonymous

    anonymous Guest

    current beta. What I don't get is the goals. We have terrible managed care and an inferior copy card and the goals go up. A flat market